2026-01-24 - Analysis Report
**Company Overview:**
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that develops and commercializes medicines for serious eye diseases, cancer, and infectious and inflammatory diseases.

**Return Rate Comparison:**
The cumulative return of REGN is 51.09%, while the S&P 500 (VOO) has a cumulative return of 126.41%. The divergence is -75.30, indicating a significant underperformance of REGN compared to the broader market.

**Yearly Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 10.0% | 22.5% | -2.0% | 1.2 | 39.6B |
| 2017-2019  | 11.0% | 27.6% | -15.0% | 1.0 | 39.8B |
| 2018-2020  | 32.0% | 27.6% | 8.0% | 0.7 | 51.2B |
| 2019-2021  | 42.0% | 27.6% | -24.0% | 0.6 | 66.9B |
| 2020-2022  | 75.0% | 25.4% | 68.0% | 0.6 | 76.5B |
| 2021-2023  | 63.0% | 24.4% | 43.0% | 0.6 | 93.1B |
| 2022-2024  | -1.0% | 40.4% | -31.0% | 0.6 | 75.5B |
| 2023-2025  | -18.0% | 57.0% | -93.0% | 0.6 | 81.8B |

**5-Day Moving Average Analysis:**
The 5-day SMA is $745.04, which is below the current price of $753.55.

**Recent Stock Price Fluctuation:**
- 5-day SMA: $745.04
- 20-day SMA: $768.45
- 60-day SMA: $732.28
The stock has a recent price fluctuation of -0.26.

**RSI and PPO Analysis:**
- RSI: 43.14 (Neutral)
- PPO: -0.70 (Bearish)
- Market Risk Indicator (MRI): 0.70 (Medium Risk)
- Recent relative divergence change: 2.10 (+) improving
- 7-day Rank change: 126 (+) rank up
- 7-day Dynamic Expected Return change: 57.30 (+) improving
- Risk Level: Medium

**News and Significant Events:**
Recent news articles from Yahoo Finance suggest that REGN may have a positive earnings report and its stock price may rebound.

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 830.04 / 1057.00 / 630.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|-----|---:|---:|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |

The quarterly earnings per share (EPS) have been stable, with a recent increase in revenue. However, the profit margins have been slightly decreasing.

**Revenue and Profitability Analysis:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

The revenue has been increasing, but the profit margin has been decreasing slightly.

**Capital and Profitability Analysis:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

The equity has been decreasing slightly, but the return on equity (ROE) has been increasing.

**Comprehensive Analysis:**
REGN has a mixed performance, with a stable EPS, increasing revenue, and slightly decreasing profit margin. The company has a medium risk profile and a buy recommendation from analysts. However, the stock price has a recent sharp decline, and the short-term moving averages are below the current price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.